NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Initi
Post# of 154184
(Total Views: 130)
Posted On: 11/26/2018 6:02:31 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Initiate Metastatic Triple Negative Breast Cancer Trial
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its November 23, 2018, receipt of FDA approval for its IND submission, allowing the company to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast cancer (“TNBC”) patients. CytoDyn has identified sites for five clinical trials, and it intends to dose its first several patients with expected initial readout during the first quarter of 2019.
“Metastatic triple-negative breast cancer (TNBC) is a deadly disease with poor prognosis due to the spread of the cancer in the blood stream.” CytoDyn Chief Medical Officer Dr. Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “Current therapies are directed to the primary tumor, rather than the movement or spread of the cancer in the blood stream… In order to really impact cancer survival, we need to control the metastasis. We recently discovered that the receptor CCR5, which is required for the entry of HIV into immune cells, is also expressed on cancer cells. CCR5 on cancer cells promotes the cancer cell spread in the blood stream. CCR5 controls homing of metastasis to the bones, brain, lung and other sites. PRO 140 binds CCR5 in cancer cells, so we believe we can now directly target the metastatic process. Our previously published studies of 2,200 breast cancer patients showed that CCR5 is overexpressed on over 95% of TNBC patient tumors, making CCR5 an ideal target for this disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced its November 23, 2018, receipt of FDA approval for its IND submission, allowing the company to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast cancer (“TNBC”) patients. CytoDyn has identified sites for five clinical trials, and it intends to dose its first several patients with expected initial readout during the first quarter of 2019.
“Metastatic triple-negative breast cancer (TNBC) is a deadly disease with poor prognosis due to the spread of the cancer in the blood stream.” CytoDyn Chief Medical Officer Dr. Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “Current therapies are directed to the primary tumor, rather than the movement or spread of the cancer in the blood stream… In order to really impact cancer survival, we need to control the metastasis. We recently discovered that the receptor CCR5, which is required for the entry of HIV into immune cells, is also expressed on cancer cells. CCR5 on cancer cells promotes the cancer cell spread in the blood stream. CCR5 controls homing of metastasis to the bones, brain, lung and other sites. PRO 140 binds CCR5 in cancer cells, so we believe we can now directly target the metastatic process. Our previously published studies of 2,200 breast cancer patients showed that CCR5 is overexpressed on over 95% of TNBC patient tumors, making CCR5 an ideal target for this disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)